Clinical trial aimed at new therapeutic approch against HAM patients by pentosan polysulphate

Clinical trial aimed at new therapeutic approch against HAM patients by pentosan polysulphate - Clinical trial against HAM patients by pentosan polysulphate

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004492

Enrollment

Registered

2010-11-01

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HTLV-I associated myelopathy (HAM)

Interventions

Subcutaneous injection once a week (1st 25mg, 2nd 50mg, 100 mg after 3rd injection) for 8 weeks followed by observation for another 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HAM patients who fulfilled the diagnostic criteria of WHO

Exclusion criteria

Exclusion criteria: patients who both prothrombin time and activated partial thromboplastin time are more than normal ranges at screening test

Design outcomes

Primary

Measure	Time frame
Improvement of neurological signs, Improvement of neurogenic bladder, Decrease of HTLV-I proviral load in peripheral blood, Check of side effects	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026